An acute clinical trial evaluating the cardiovascular effects of an herbal ephedra-caffeine weight loss product in healthy overweight adults

D. Kalman, T. Incledon, Ignacio Gaunaurd, H. Schwartz, D. Krieger

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Objective: This study was undertaken to determine the acute effects of a commercial weight loss supplement containing herbal ephedrine and caffeine on cardiovascular function in healthy overweight adults. Design: Randomized double blind clinical trial evaluating the cardiovascular effects of an ephedra - caffeine (Xenadrine™; XEN) based herbal product vs placebo (PLA). Subjects: Twenty-seven healthy overweight adults (age 21-60y; body mass index ≥ 25 kg/m2). Measurements: Systolic and diastolic blood pressure, heart rate, serial electrocardiograms (EKG) and Doppler echocardiograms. Results: A comparison of means between the groups indicated no statistically significant differences at the start of the study for the variables above. There were no serious adverse events. When examining the effects of XEN vs PLA on cardiovascular health/function, there were no significant effects observed in heart rate, systolic blood pressure, diastolic blood pressure, left ventricular ejection fraction, heart valve function or in cardiovascular physiology within the parameters measured. Conclusion: These findings indicate that, over a 14-day period, ingestion of the commercial weight loss supplement in a healthy overweight population did not produce any noticeable cardiovascular side effects.

Original languageEnglish (US)
Pages (from-to)1363-1366
Number of pages4
JournalInternational Journal of Obesity
Volume26
Issue number10
DOIs
StatePublished - Oct 2002

Fingerprint

Ephedra
caffeine
Caffeine
Weight Loss
clinical trials
weight loss
diastolic blood pressure
electrocardiography
Clinical Trials
systolic blood pressure
Blood Pressure
placebos
heart rate
heart valves
ephedrine
acute effects
body mass index
Electrocardiography
physiology
Heart Rate

Keywords

  • Caffeine
  • Cardiovascular
  • Ephedrine
  • Sympathomimetic
  • Weight loss

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Public Health, Environmental and Occupational Health
  • Endocrinology
  • Food Science
  • Endocrinology, Diabetes and Metabolism

Cite this

An acute clinical trial evaluating the cardiovascular effects of an herbal ephedra-caffeine weight loss product in healthy overweight adults. / Kalman, D.; Incledon, T.; Gaunaurd, Ignacio; Schwartz, H.; Krieger, D.

In: International Journal of Obesity, Vol. 26, No. 10, 10.2002, p. 1363-1366.

Research output: Contribution to journalArticle

Kalman, D. ; Incledon, T. ; Gaunaurd, Ignacio ; Schwartz, H. ; Krieger, D. / An acute clinical trial evaluating the cardiovascular effects of an herbal ephedra-caffeine weight loss product in healthy overweight adults. In: International Journal of Obesity. 2002 ; Vol. 26, No. 10. pp. 1363-1366.
@article{f00811c97c3e4391be277e0e0a109e51,
title = "An acute clinical trial evaluating the cardiovascular effects of an herbal ephedra-caffeine weight loss product in healthy overweight adults",
abstract = "Objective: This study was undertaken to determine the acute effects of a commercial weight loss supplement containing herbal ephedrine and caffeine on cardiovascular function in healthy overweight adults. Design: Randomized double blind clinical trial evaluating the cardiovascular effects of an ephedra - caffeine (Xenadrine™; XEN) based herbal product vs placebo (PLA). Subjects: Twenty-seven healthy overweight adults (age 21-60y; body mass index ≥ 25 kg/m2). Measurements: Systolic and diastolic blood pressure, heart rate, serial electrocardiograms (EKG) and Doppler echocardiograms. Results: A comparison of means between the groups indicated no statistically significant differences at the start of the study for the variables above. There were no serious adverse events. When examining the effects of XEN vs PLA on cardiovascular health/function, there were no significant effects observed in heart rate, systolic blood pressure, diastolic blood pressure, left ventricular ejection fraction, heart valve function or in cardiovascular physiology within the parameters measured. Conclusion: These findings indicate that, over a 14-day period, ingestion of the commercial weight loss supplement in a healthy overweight population did not produce any noticeable cardiovascular side effects.",
keywords = "Caffeine, Cardiovascular, Ephedrine, Sympathomimetic, Weight loss",
author = "D. Kalman and T. Incledon and Ignacio Gaunaurd and H. Schwartz and D. Krieger",
year = "2002",
month = "10",
doi = "10.1038/sj.ijo.0802061",
language = "English (US)",
volume = "26",
pages = "1363--1366",
journal = "International Journal of Obesity",
issn = "0307-0565",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - An acute clinical trial evaluating the cardiovascular effects of an herbal ephedra-caffeine weight loss product in healthy overweight adults

AU - Kalman, D.

AU - Incledon, T.

AU - Gaunaurd, Ignacio

AU - Schwartz, H.

AU - Krieger, D.

PY - 2002/10

Y1 - 2002/10

N2 - Objective: This study was undertaken to determine the acute effects of a commercial weight loss supplement containing herbal ephedrine and caffeine on cardiovascular function in healthy overweight adults. Design: Randomized double blind clinical trial evaluating the cardiovascular effects of an ephedra - caffeine (Xenadrine™; XEN) based herbal product vs placebo (PLA). Subjects: Twenty-seven healthy overweight adults (age 21-60y; body mass index ≥ 25 kg/m2). Measurements: Systolic and diastolic blood pressure, heart rate, serial electrocardiograms (EKG) and Doppler echocardiograms. Results: A comparison of means between the groups indicated no statistically significant differences at the start of the study for the variables above. There were no serious adverse events. When examining the effects of XEN vs PLA on cardiovascular health/function, there were no significant effects observed in heart rate, systolic blood pressure, diastolic blood pressure, left ventricular ejection fraction, heart valve function or in cardiovascular physiology within the parameters measured. Conclusion: These findings indicate that, over a 14-day period, ingestion of the commercial weight loss supplement in a healthy overweight population did not produce any noticeable cardiovascular side effects.

AB - Objective: This study was undertaken to determine the acute effects of a commercial weight loss supplement containing herbal ephedrine and caffeine on cardiovascular function in healthy overweight adults. Design: Randomized double blind clinical trial evaluating the cardiovascular effects of an ephedra - caffeine (Xenadrine™; XEN) based herbal product vs placebo (PLA). Subjects: Twenty-seven healthy overweight adults (age 21-60y; body mass index ≥ 25 kg/m2). Measurements: Systolic and diastolic blood pressure, heart rate, serial electrocardiograms (EKG) and Doppler echocardiograms. Results: A comparison of means between the groups indicated no statistically significant differences at the start of the study for the variables above. There were no serious adverse events. When examining the effects of XEN vs PLA on cardiovascular health/function, there were no significant effects observed in heart rate, systolic blood pressure, diastolic blood pressure, left ventricular ejection fraction, heart valve function or in cardiovascular physiology within the parameters measured. Conclusion: These findings indicate that, over a 14-day period, ingestion of the commercial weight loss supplement in a healthy overweight population did not produce any noticeable cardiovascular side effects.

KW - Caffeine

KW - Cardiovascular

KW - Ephedrine

KW - Sympathomimetic

KW - Weight loss

UR - http://www.scopus.com/inward/record.url?scp=0036800631&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036800631&partnerID=8YFLogxK

U2 - 10.1038/sj.ijo.0802061

DO - 10.1038/sj.ijo.0802061

M3 - Article

C2 - 12355332

AN - SCOPUS:0036800631

VL - 26

SP - 1363

EP - 1366

JO - International Journal of Obesity

JF - International Journal of Obesity

SN - 0307-0565

IS - 10

ER -